Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Guggenheim Partners Oncology Day Transcript

Feb 14, 2019 / 06:00PM GMT
Release Date Price: R$14.61
Unidentified Analyst

Okay. All right. Great. So thanks, everybody, for joining us. Really, really pleased to have Eli Lilly here with us today. Just to my right is Anne White. She's President of Lilly Oncology. And then to Anne's right is Dr. Levi Garraway. He's Head of Oncology, R&D. We also have members of the IR team in the audience here. So thanks to the team for joining us.

Questions & Answers

Unidentified Analyst

But I'm going to jump right into questions. And again, I think, maybe -- most importantly, Anne, maybe you can talk to us about the Lilly strategy. Obviously, you guys are working to kind of rebuild and refocus the business. And I don't know, have we closed the Loxo -- actually it was this week?

Anne E. White
Eli Lilly and Company - Senior VP & President of Lilly Oncology

We're actually planning to close tomorrow.

Unidentified Analyst;Anne E. White
Eli Lilly and Company -

Tomorrow. Okay. So I thought it was this week. Okay.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot